1 unchanged sentence
Director and Officer Trading Arrangements
−Removed: During the last fiscal quarter, the following directors and “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K:
−Removed: On March 13, 2026 , Alan Russell , Chief Scientific Officer and Director , adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of up to 200,000 shares of our common stock.
−Removed: The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
−Removed: The duration of the trading arrangement is until July 1, 2027 , or earlier if all transactions under the trading arrangement are completed.
−Removed: No other directors or “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K, during the last fiscal quarter.
+Added: No directors or “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K, during the last fiscal quarter.
See Exhibit Index.
2 unchanged sentences
Exhibit Description
−Removed: Amended and Restated Outside Director Compensation Policy
+Added: Asset Purchase Agreement
Filed herewith
−Removed: Letter Agreement between the Registrant and R.
−Removed: Michael Carruthers.
−Removed: February 26, 2026
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
22 unchanged sentences
Filed herewith
−Removed: Ù Indicates management contract or compensation plan
+Added: # Certain confidential information contained in this exhibit has been omitted because it is both (i) not material;
+Added: and (ii) the type that the registrant customarily and actually treats as private or confidential.
†The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
+Added: August 6, 2026
EDGEWISE THERAPEUTICS, INC.
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.